VG-3927 First-In-Human Phase 1 Trial
This completed double-blind, placebo-controlled Phase 1 clinical trial evaluated VG-3927 in single and multiple ascending doses (SAD/MAD) in healthy volunteers. The study was designed to evaluate safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Learn more about the trial at clinicaltrials.gov (NCT06343636).
Expanded Access Policy
Vigil Neuroscience, Inc. (“Vigil”) is dedicated to developing innovative, safe, and effective therapies for rare and common neurodegenerative diseases.
Expanded Access, also referred to as Compassionate Use, is the use of an investigational therapy outside of a clinical trial. Currently, Vigil does not have an Expanded Access or Compassionate Use Program and the only way to obtain access to Vigil’s investigational therapies is to participate in a clinical trial. We may re-evaluate the status of our Expanded Access Policy as development of our therapies progresses.
We understand that for people living with neurodegenerative diseases, waiting for approved treatments is difficult. We recognize the urgency for new therapies to be developed and are steadfast in our commitment to people living with rare and common neurodegenerative diseases.
For additional information on our clinical trials or questions about our Expanded Access Policy, please contact trials@vigilneuro.com.